局所進行胃癌の手術を受ける患者に対するS-1とイリノテカンの併用療法

基本情報

NCT ID: NCT00134095
ステータス: 不明
試験のフェーズ: 第2相
試験タイプ: 介入
目標被験者数: 70
治験依頼者名: National Cancer Institute (NCI)

概要

RATIONALE: Drugs used in chemotherapy, such as S-1 and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving chemotherapy before surgery may shrink the tumor so that it can be completely removed. PURPOSE: This phase II trial is studying how well giving S-1 together with irinotecan works in treating patients who are undergoing surgery for locally advanced stomach cancer.

対象疾患

Gastric Cancer

介入

irinotecan hydrochloride(DRUG)

tegafur-gimeracil-oteracil potassium(DRUG)

adjuvant therapy(PROCEDURE)

conventional surgery(PROCEDURE)

neoadjuvant therapy(PROCEDURE)

依頼者（Sponsor）

Fukushima Medical University Hospital(OTHER)

実施施設 (7)

Asahikawa Kosei General Hospital

Asahikawa, Hokkaido, Japan

山本小児科クリニック

Noshiro, Akita, Japan

鶴岡市立荘内病院

Tsuruoka, Yamagata, Japan

神戸市立医療センター中央市民病院

Kobe, Hyōgo, Japan

公立大学法人　福島県立医科大学附属病院

Fukushima, Fukushima, Japan

岩手医科大学附属病院

Morioka, Iwate, Japan

山形県立中央病院

Yamagata, Yamagata, Japan